Companion Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

Companion Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

  • April 2020 •
  • 113 pages •
  • Report ID: 5891589 •
  • Format: PDF
The growth of the global companion diagnostics market can be attributed to the rising focus on personalized medicine and the co-development of drug and diagnostic technologies. In addition, rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. One of the major factors driving the growth of the companion diagnostics market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics, in order to focus on cost regulations, there has been a significant number of opportunities for its applications in indications, like cancer, cardiovascular and neurological disorders, etc.

Key Market Trends
Application in Lung Cancer is expected to Dominate the Market Over the Forecast Period

Companion diagnostic tests (CDXs) are considered mandatory for decision-making for treatment with targeted therapies in Lung cancer. The emergence of immunotherapy has also given rise to the development of CDXs. Therascreen EGFR RGQ PCR Kit (Qiagen), Cobas EGFR Mutation Test v2 (Roche Molecular Systems) are some of the many companion diagnostics available for Lung cancer therapies.

Moreover, lung cancer is the most common form of cancer, and also causes most cancer-related deaths globally, as per 2018 report by the World Health Organization. This translates to more demand for lung cancer companion diagnostics, which is expected to help the market growth.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall companion diagnostics market, with the United States emerging as the major contributor to the market. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, which is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostic assays are classified as IVD class III products, which represents a high-risk category, and consequently, the highest level of regulatory control. Hence, owing to high healthcare technology adoption rates and increasing demand for personalized medicine, the market for companion diagnostics in the United States is expected to register a substantial growth rate during the forecast period.

Competitive Landscape
The presence of major market players, such as Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, Biomerieux SA, and Qiagen NV, is, in turn, increasing the overall competitive rivalry of the market. But the issues associated with the high development cost and poor reimbursement are affecting the market negatively. However, the rising focus of companies toward personalized medicine, co-development activities, and increased cases of adverse drug reactions is expected to boost the competitive rivalry in the market studied.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

We are very sorry, but an error occurred.
Please contact if the problem remains.